151 related articles for article (PubMed ID: 16476947)
1. Is protracted low-dose temozolomide feasible in glioma patients?
Tosoni A; Cavallo G; Ermani M; Scopece L; Franceschi E; Ghimenton C; Gardiman M; Pasetto L; Blatt V; Brandes AA
Neurology; 2006 Feb; 66(3):427-9. PubMed ID: 16476947
[TBL] [Abstract][Full Text] [Related]
2. Is protracted low-dose temozolomide feasible in glioma patients?
Wong ET
Neurology; 2006 Aug; 67(3):543-4; author reply 543-4. PubMed ID: 16894133
[No Abstract] [Full Text] [Related]
3. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules.
Tolcher AW; Gerson SL; Denis L; Geyer C; Hammond LA; Patnaik A; Goetz AD; Schwartz G; Edwards T; Reyderman L; Statkevich P; Cutler DL; Rowinsky EK
Br J Cancer; 2003 Apr; 88(7):1004-11. PubMed ID: 12671695
[TBL] [Abstract][Full Text] [Related]
4. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
5. New approaches for temozolomide therapy: use in newly diagnosed glioma.
Stupp R; Newlands E
Semin Oncol; 2001 Aug; 28(4 Suppl 13):19-23. PubMed ID: 11550135
[TBL] [Abstract][Full Text] [Related]
6. Dose-dense temozolomide regimens: antitumor activity, toxicity, and immunomodulatory effects.
Neyns B; Tosoni A; Hwu WJ; Reardon DA
Cancer; 2010 Jun; 116(12):2868-77. PubMed ID: 20564393
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma.
Wick A; Felsberg J; Steinbach JP; Herrlinger U; Platten M; Blaschke B; Meyermann R; Reifenberger G; Weller M; Wick W
J Clin Oncol; 2007 Aug; 25(22):3357-61. PubMed ID: 17664483
[TBL] [Abstract][Full Text] [Related]
8. [Temodal--an alkylating cytostatic agent. Effectiveness in patients with malignant gliomas].
Matsko MV
Vopr Onkol; 2012; 58(3):425-8. PubMed ID: 22888663
[No Abstract] [Full Text] [Related]
9. Temozolomide for melanoma: new toxicities and new opportunities.
Gajewski TF
J Clin Oncol; 2004 Feb; 22(4):580-1. PubMed ID: 14726506
[No Abstract] [Full Text] [Related]
10. Efficacy of protracted dose-dense temozolomide in patients with recurrent high-grade glioma.
Abacioglu U; Caglar HB; Yumuk PF; Akgun Z; Atasoy BM; Sengoz M
J Neurooncol; 2011 Jul; 103(3):585-93. PubMed ID: 20878446
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
[TBL] [Abstract][Full Text] [Related]
12. Do glioma patients derive any therapeutic benefit from taking a higher cumulative dose of temozolomide regimens?: a meta-analysis.
Sun H; Du S; Liao G; Xie X; Ren C; Yuan YW
Medicine (Baltimore); 2015 May; 94(20):e827. PubMed ID: 25997057
[TBL] [Abstract][Full Text] [Related]
13. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications.
Su YB; Sohn S; Krown SE; Livingston PO; Wolchok JD; Quinn C; Williams L; Foster T; Sepkowitz KA; Chapman PB
J Clin Oncol; 2004 Feb; 22(4):610-6. PubMed ID: 14726505
[TBL] [Abstract][Full Text] [Related]
14. Future directions for temozolomide therapy.
Yung WK
Semin Oncol; 2001 Aug; 28(4 Suppl 13):43-6. PubMed ID: 11550138
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of neoadjuvant 1, 3-bis (2-chloroethyl)-1-nitrosourea and temozolomide for newly diagnosed anaplastic glioma: a North American Brain Tumor Consortium Trial.
Chang SM; Prados MD; Yung WK; Fine H; Junck L; Greenberg H; Robins HI; Mehta M; Fink KL; Jaeckle KA; Kuhn J; Hess K; Schold C
Cancer; 2004 Apr; 100(8):1712-6. PubMed ID: 15073861
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
[TBL] [Abstract][Full Text] [Related]
17. Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours.
Baruchel S; Diezi M; Hargrave D; Stempak D; Gammon J; Moghrabi A; Coppes MJ; Fernandez CV; Bouffet E
Eur J Cancer; 2006 Sep; 42(14):2335-42. PubMed ID: 16899365
[TBL] [Abstract][Full Text] [Related]
18. Intravenous administration of temozolomide as a useful alternative over oral treatment with temozolomide capsules in patients with gliomas.
Motomura K; Natsume A; Wakabayashi T
J Neurooncol; 2012 Jan; 106(1):209-11. PubMed ID: 21725854
[No Abstract] [Full Text] [Related]
19. Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.
Nicholson HS; Kretschmar CS; Krailo M; Bernstein M; Kadota R; Fort D; Friedman H; Harris MB; Tedeschi-Blok N; Mazewski C; Sato J; Reaman GH
Cancer; 2007 Oct; 110(7):1542-50. PubMed ID: 17705175
[TBL] [Abstract][Full Text] [Related]
20. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies.
Brada M; Judson I; Beale P; Moore S; Reidenberg P; Statkevich P; Dugan M; Batra V; Cutler D
Br J Cancer; 1999 Nov; 81(6):1022-30. PubMed ID: 10576660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
